Azithromycin Suspension Award

SOL #: SPE2D2-25-D-0010Award Notice

Overview

Buyer

DEPT OF DEFENSE

Defense Logistics Agency

DLA TROOP SUPPORT

PHILADELPHIA, PA, 19111, United States

Place of Performance

Laurelton, NY

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Original Source

https://sam.gov/opp/f444d2d3e1b44ac492478c6705397db8/view

Timeline

Posted

Apr 8, 2025

Last Updated

Apr 6, 2026

Qualification Details

Fit reasons

NAICS alignment with historical contract wins in similar service areas.
Scope strongly matches core technical capabilities and delivery model.

Risks

Past performance thresholds may require one additional teaming partner.
Potential clarification needed on staffing minimums before bid/no-bid.

Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Logistics Agency (DLA) Troop Support has exercised Option 1 on Contract SPE2D2-25-D-0010 with Puracap Laboratories LLC for the continued supply of Azithromycin Suspension. This action covers the period from April 21, 2026, through April 20, 2027. The original contract was valued at an estimated $800,796.80 over a 5-year period.

Contract Details

Contract Number: SPE2D2-25-D-0010
Contractor: Puracap Laboratories LLC
Product: Azithromycin Suspension (15 ML, 22.5 ML, and 30 ML)
Original Estimated Value: $800,796.80
Original Period of Performance: 5 years
Option Exercised: Option #232 1
Option Period: April 21, 2026, through April 20, 2027
Awarding Agency: DLA Troop Support, DEPT OF DEFENSE
Place of Performance: Epic Pharma LLC, Laurelton, NY 11413, United States
Product Service Code: 6505 - Drugs And Biologicals
Set-Aside: None specified

Background

The original contract, SPE2D2-25-D-0010, was awarded to Puracap Laboratories LLC following Solicitation SPE2D2-25-R-0001. The award incorporated Amendment 0001, Puracap's offer, and final proposal revisions. The contract includes various Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) clauses applicable to commercial products and services.

Pharmaceutical Prime Vendors

The contract supports distribution through current Pharmaceutical Prime Vendors including Amerisource Bergen Drug Co., Cardinal Health, Dakota Drug, Inc., DMS Pharmaceutical Group Inc., and McKesson Corp.